Cargando…
Identifying, highlighting and reducing polypharmacy in a UK hospice inpatient unit using improvement Science methods
Polypharmacy, the concurrent use of multiple medications by one individual is a growing global issue driven by an ageing population and increasing prevalence of multi-morbidity[1]. Polypharmacy can be problematic: interactions between medications, reduced adherence to medication, burden of medicatio...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
British Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348587/ https://www.ncbi.nlm.nih.gov/pubmed/28321300 http://dx.doi.org/10.1136/bmjquality.u211783.w5035 |
_version_ | 1782514263497113600 |
---|---|
author | Phippen, Alison Pickard, Jennie Steinke, Douglas Cope, Matt Roberts, Dai |
author_facet | Phippen, Alison Pickard, Jennie Steinke, Douglas Cope, Matt Roberts, Dai |
author_sort | Phippen, Alison |
collection | PubMed |
description | Polypharmacy, the concurrent use of multiple medications by one individual is a growing global issue driven by an ageing population and increasing prevalence of multi-morbidity[1]. Polypharmacy can be problematic: interactions between medications, reduced adherence to medication, burden of medication to patients, administration time, increased risk of errors and increased cost. Quality improvement methods were applied to identify and highlight polypharmacy patients with the aim of reducing their average number of regular tablets/capsules per day by 25%. The project was delivered within a UK based 27 bedded hospice inpatient unit. A series of PDSA cycles studied interventions focusing on the identification of patients with polypharmacy, the highlighting of these patients to prescribers for review and the views of patients about their medication. For the purposes of the study, polypharmacy was defined as greater than ten regular medicines and/or greater than twenty regular tablets/capsules each day. The interventions tested included patients on regular paracetamol and strong opioids being offered a trial without regular paracetamol, a constipation guide promoting the use of combination laxatives, education of prescribers around dose strengths, checklist of recommendations was placed in case notes and a sticker was used on the medicine chart to highlight patients in need of polypharmacy review. The introduction of a trial without paracetamol and a laxative guide led to reductions in polypharmacy. The sticker and checklist were successful interventions for highlighting patients with polypharmacy. Quality improvement methods were used to plan, try, test and implement simple interventions for patients on the hospice inpatient unit. This has led to a 25% reduction in the average regular tablet/capsules burden , a 16% reduction in the average number of regular medications and a 30% reduction in the average volume of liquid medication per patient without an increase in the use of ‘as required’ medication or length of stay. |
format | Online Article Text |
id | pubmed-5348587 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | British Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-53485872017-03-20 Identifying, highlighting and reducing polypharmacy in a UK hospice inpatient unit using improvement Science methods Phippen, Alison Pickard, Jennie Steinke, Douglas Cope, Matt Roberts, Dai BMJ Qual Improv Rep BMJ Quality Improvement Programme Polypharmacy, the concurrent use of multiple medications by one individual is a growing global issue driven by an ageing population and increasing prevalence of multi-morbidity[1]. Polypharmacy can be problematic: interactions between medications, reduced adherence to medication, burden of medication to patients, administration time, increased risk of errors and increased cost. Quality improvement methods were applied to identify and highlight polypharmacy patients with the aim of reducing their average number of regular tablets/capsules per day by 25%. The project was delivered within a UK based 27 bedded hospice inpatient unit. A series of PDSA cycles studied interventions focusing on the identification of patients with polypharmacy, the highlighting of these patients to prescribers for review and the views of patients about their medication. For the purposes of the study, polypharmacy was defined as greater than ten regular medicines and/or greater than twenty regular tablets/capsules each day. The interventions tested included patients on regular paracetamol and strong opioids being offered a trial without regular paracetamol, a constipation guide promoting the use of combination laxatives, education of prescribers around dose strengths, checklist of recommendations was placed in case notes and a sticker was used on the medicine chart to highlight patients in need of polypharmacy review. The introduction of a trial without paracetamol and a laxative guide led to reductions in polypharmacy. The sticker and checklist were successful interventions for highlighting patients with polypharmacy. Quality improvement methods were used to plan, try, test and implement simple interventions for patients on the hospice inpatient unit. This has led to a 25% reduction in the average regular tablet/capsules burden , a 16% reduction in the average number of regular medications and a 30% reduction in the average volume of liquid medication per patient without an increase in the use of ‘as required’ medication or length of stay. British Publishing Group 2017-03-10 /pmc/articles/PMC5348587/ /pubmed/28321300 http://dx.doi.org/10.1136/bmjquality.u211783.w5035 Text en © 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/http://creativecommons.org/licenses/by-nc/2.0/legalcode |
spellingShingle | BMJ Quality Improvement Programme Phippen, Alison Pickard, Jennie Steinke, Douglas Cope, Matt Roberts, Dai Identifying, highlighting and reducing polypharmacy in a UK hospice inpatient unit using improvement Science methods |
title | Identifying, highlighting and reducing polypharmacy in a UK hospice inpatient unit using improvement Science methods |
title_full | Identifying, highlighting and reducing polypharmacy in a UK hospice inpatient unit using improvement Science methods |
title_fullStr | Identifying, highlighting and reducing polypharmacy in a UK hospice inpatient unit using improvement Science methods |
title_full_unstemmed | Identifying, highlighting and reducing polypharmacy in a UK hospice inpatient unit using improvement Science methods |
title_short | Identifying, highlighting and reducing polypharmacy in a UK hospice inpatient unit using improvement Science methods |
title_sort | identifying, highlighting and reducing polypharmacy in a uk hospice inpatient unit using improvement science methods |
topic | BMJ Quality Improvement Programme |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348587/ https://www.ncbi.nlm.nih.gov/pubmed/28321300 http://dx.doi.org/10.1136/bmjquality.u211783.w5035 |
work_keys_str_mv | AT phippenalison identifyinghighlightingandreducingpolypharmacyinaukhospiceinpatientunitusingimprovementsciencemethods AT pickardjennie identifyinghighlightingandreducingpolypharmacyinaukhospiceinpatientunitusingimprovementsciencemethods AT steinkedouglas identifyinghighlightingandreducingpolypharmacyinaukhospiceinpatientunitusingimprovementsciencemethods AT copematt identifyinghighlightingandreducingpolypharmacyinaukhospiceinpatientunitusingimprovementsciencemethods AT robertsdai identifyinghighlightingandreducingpolypharmacyinaukhospiceinpatientunitusingimprovementsciencemethods |